In the original study plan, the target number of cases was 15 post-COVID-19 patients. However, the number of patients infected with COVID-19 at our hospital decreased dramatically after the start of the study, and it was expected to be difficult to recruit 15 post-COVID-19 patients within the study period. During the course of the study, we decided to expand the study to include post-vaccination cohorts of subjects considering the clinical significance of measuring the antibody titer obtained from the COVID-19vaccine . When 15 subjects were recruited, 3 subjects did not show any increase in antibody titer for COVID-19, so we conducted the study on 3 more subjects (18 subjects in total) from the post-vaccination cohort.
/
試験デバイスを使った採血は、被験者に合併症をおこすことなく、順調に終了した。
The blood collection using the test device was completed successfully without any complications to the subject.
We measured Roche's SARS-CoV-2 anti-S antibody using blood sample A generated by incubating whole blood absorbed by filter paper in the device with 0.5% Tween-added SDS solution under various conditions, and serum B isolated from venous blood, and confirmed that there was a correlation between the values of A and B. It was suggested that the minimally invasive blood collection device may be useful for measuring anti-S antibodies against COVID-19.
We measured COVID-19 anti-S antibodies in blood collected using a minimally invasive blood collection device and in serum collected by venous blood collection, and found that there was a correlation between the two samples.
2021年12月01日
3 IPDシェアリング
/
無
No
/
計画なし
None
管理的事項
研究の種別
特定臨床研究
届出日
令和3年10月26日
臨床研究実施計画番号
jRCTs052200157
1 特定臨床研究の実施体制に関する事項及び特定臨床研究を行う施設の構造設備に関する事項
(1)研究の名称
低侵襲型採血デバイスOneDraw™を用いたSARS-CoV-2抗体価測定に関する探索的研究
Exploratory research on Anti-SARS-CoV-2 testing by the Blood Collection Device OneDraw